Regents Of The University Of California Cytom X Therapeutics, Inc. Transaction History

Regents Of The University Of California

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 25, 2022	SELL	$2.67 - $4.68 $100,125 - $175,500	-37,500 Closed	0 $0
Q3 2021 Oct 20, 2021	SELL	$4.32 - $6.43 $162,000 - $241,125	-37,500 Reduced 50.0%	37,500 $191,000
Q1 2021 Apr 20, 2021	BUY	$6.6 - $9.0 $495,000 - $675,000	75,000 New	75,000 $580,000
Q3 2017 Nov 20, 2017	SELL	$13.53 - $18.17 $493,831 - $663,186	-36,499 Closed	0 $0
Q2 2017 Aug 21, 2017	BUY	N/A	36,499	36,499 $566,000

50.7M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $66.6M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Regents Of The University Of California, based on Form 13F filings with the SEC.

Stay updated on Regents Of The University Of California with notifications on news.